Beyond best practices: Strict scrutiny as a regulatory model for race-specific medicines

Journal of Law, Medicine and Ethics

Volumn 36, Issue 3, 2008, Pages 491-497

  Obasogie, Osagie K ^a,b,c  

^a University of California   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Center for Genetics and Society

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; GENETICS; HUMAN; PHARMACOGENETICS; RACE; UNITED STATES;

CONTINENTAL POPULATION GROUPS; DRUG APPROVAL; HUMANS; PHARMACOGENETICS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 50249165352     PISSN: 10731105     EISSN: 1748720X     Source Type: Journal    
DOI: 10.1111/j.1748-720X.2008.296.x     Document Type: Conference Paper

References (37)

1. J. C. Long Human Genetic Variation: The Mechanisms and Results of Microevolution Understanding Race: A Project of the American Anthropological Association," available at http://www.understandingrace.org/resources/ papersactiv-ity.html (last visited July 18, 2008 I. H. Lopez The Social Construction of Race: Some Observations on Illusion, Fabrication, and Choice Harvard Civil Rights and Civil Liberties Law Review 29, no. 1 (1994 1 62.
2. N. Adler et al. Reaching for a Healthier Life: Facts on Socio-economic Status and Health in the U.S. 2007 The John D. and Catherine T. Macarthur Foundation Research Network on Socioeconomic Status and Health B. D. Smedley, A. Y. Smith, and A. R. Nelson, eds., Unequal Treatment: Understanding Racial and Ethnic Disparities in Health Care, Institute of Medicine, 2003.
3. R. March Pharmacogenomics: The Genomics of Drug Response Yeast 17, no. 1 2000 16 21.
4. See E. Gonzalez Burchard et al. The Importance of Race and Ethnic Background in Biomedical Research and Clinical Practice New England Journal of Medicine 348, no. 12 (March 20, 2003 1170 1172 A. S. Daar and P. Singer Pharmacogenomics and Geographical Ancestry: Implications for Drug Development and Global Health Nature Reviews Genetics 6, no. 3 (October 2005 241 246.
5. See A. Bowcock et al. High Resolution of Human Evolutionary Trees with Polymorphic Microsatellites Nature 368, no. 6470 (1994 455 457 A. Bowcock et al. Drift, Admixture, and Selection in Human Evolution: A Study with DNA Polymorphisms Proceeding of the National Academy of Sciences 88, no. 3 (1991 839 843.
6. N. Rosenburg et al. Genetic Structure of Human Populations Science 298, no. 5602 (2002 2381 2385 M. J. Bamshad et al. Human Population Genetic Structure and Inference of Group Membership American Journal of Human Genetics 72, no. 3 (2003 578 589 J. Mountain et al. Multilocus Genotypes: A Tree of Individuals, and Human Evolutionary History American Journal of Human Genetics 61, no. 3 (1997 705 718.
7. N. Risch et al. Categorization of Humans in Biomedical Research: Genes, Race and Disease Genome Biology 3, no. 7 (2002 1 12.
8. See Gonzalez Burchard et al., supra note 4.
9. J. L. Graves What We Know and What We Don't Know: Human Genetic Variation and the Social Construction of Race June 7, 2006, Social Science Research Council Is Race Real?, available at http://raceandgenomics.ssrc.org/Graves/ (last visited May 20, 2008).
10. Bolnick notes the following: [A]lthough this body of work emphasizes the individual as the crucial unit of analysis, individual ancestry inference is closely tied to our understanding of human groups and the distribution of genetic variation among them. Inferring an individual's genetic ancestry entails deciding that his or her DNA was inherited from a certain group or groups, and that cannot be accomplished unless one first distinguishes groups that differ genetically in some way. Thus, even such individually-oriented genetic research has implications for our understanding of race and the pattern of human biological diversity. D. Bolnick Individual Ancestry Inference and the Reification of Race as a Biological Phenomenon in B. Koenig, S. Soo-Jin Lee, and S. Richardson, eds., Revisiting Race in a Genomic Age (forthcoming 2008) (manuscript at 2, on file with author).
11. Bolnick states that the fact that structure identifies a particular number of clusters is insignificant: it does so simply because the user told it to do so. What is more important is that structure provides a way to determine the value of K that is most appropriate for the dataset in question (i.e. the most likely number of clusters or populations represented.) The 'best' value of K is the one that maximizes the probability of observing that set of data.... However, it is not entirely straightforward to determine the true number of genetic clusters in a given dataset for three reasons...[:] First, because it is computationally difficult,... structure provides only an approximation.... Second, if a dataset is complex, different runs of structure may produce substantially different results.... Third, the underlying model used in the structure program is not appropriate for all datasets. Id., at 7-8; manuscript on file with author.
12. R. S. Cooper et al. Race and Genomics New England Journal of Medicine 348, no. 12 (March 20, 2003 1166 1170.
13. Id.
14. W. S. Watkins Genetic Variation among World Populations: Inferences from 100 Alu Insertion Polymorphisms Genome Research 13, no. 7 (2003 1607 1618.
15. T. Duster Race and Reification in Science Science 307, no. 5712 (2005 1050 1051.
16. J. A. Franciosa and A. L. Taylor et al. African-American Heart Failure Trial (A-HeFT): Rationale, Design, and Methodology Journal of Cardiac Failure 8, no. 3 (2002 128 135.
17. A. L. Taylor et al. Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure New England Journal of Medicine 351, no. 20 (November 11, 2004 2054 2057.
18. A. Saperstein Double Checking the Race Box: Examining Inconsistency between Survey Measures of Observed and Self-Reported Race Social Forces 85, no. 1 (2006 57 74 D. R. Harris and J. J. Sim Who is Multiracial? Assessing the Complexity of Lived Race American Sociological Review 67, no. 4 (2002 614 627.
19. G. Puckrein BiDil from Another Vantage Point Health Affairs 25, no. 5 (August 15, 2006 w368 w374 G. Puckrein and C. Yancy BiDil's Impact Nature Biotechnology 23, no. 11 (November 2005 1343.
20. See Duster, supra note 15.
21. See P. Sankar and J. Kahn BiDil Race Medicine or Race Marketing Health Affairs 455, no. w5 (web exclusive October 11, 2005 455 463.
22. M. Gregg Bloche Race-Based Therapeutics New England Journal of Medicine 351, no. 20 (November 11, 2004 2035 2037, at 2036.
23. K. Ferdinand The Isosorbide-Hydralazine Story: Is There a Case for Race-Based Cardiovascular Medicine Journal of Clinical Hypertension 8, no. 3 (March 2006 156 158.
24. BiDil African-American Subset Is Surrogate for Genomics, Cmte. Chair Says The Pink Sheet 67, no. 25 (June 20, 2005).
25. F. S. Collins Foreword in Pharmacogenomics: Social, Ethical, and Clinical Dimensions (Hoboken: John Wiley and Sons, 2003).
26. M. Meadows The FDA's Drug Review Process: Ensuring Drugs Are Safe and Effective FDA Consumer 36, no. 4 (July-August 2002 19 24.
27. Dear Colleague letter from the Department of Health and Human Services, October 26, 1998, available at http://www.fda.gov/oc/ohrt/irbs/irbletr.html (last visited May 20, 2008).
28. The Slaughterhouse Cases, 83 U.S. 36, 71 (1873).
29. Gruetter v. Bollinger, 539 U.S. 306, 326 (2003).
30. Richmond v. J. A. Croson, 488 U.S. 469, 493 (1989).
31. Id., at 494.
32. E. Lillquist and C. Sullivan The Law and Genetics of Racial Profiling in Medicine Harvard Civil Rights and Civil liberties law Review 39, no. 2 (2004 391 484.
33. J. Kahn Genes, Race, and Population: Avoiding a Collision of Categories American Journal of Public Health 96, no. 11 (2006 1965 1970.
34. D. Roberts Legal Constraints on the Use of Biomedical Research: Toward a Social Justice Framework Journal of law, Medicine & Ethics 24, no. 3 (2006 526 534.
35. D. Winickoff and O. Obasogie Race-Specific Drugs: Regulatory Trends and Public Policy Trends in Pharmacological Sciences 29, no. 6 (2008 277 279.
36. C. Rados Advisory Committees: Critical to the FDA's Product Review Process FDA Consumer Magazine 38, no. 1 (January-February 2004 available at http://www.fda.gov/fdac/features/2004/l04_adv.html (last visited July 17, 2008).
37. Richmond v. J. A. Croson, 488 U.S.